[citation report] Safety of repeated doses of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine in adults and adolescents

Cited by 7 publications

(9 citation statements)

References 15 publications

(26 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A retrospective VSD study identified 68,915 adolescents and adults who had received an initial dose of Tdap and then received another Td-containing vaccine, either a second Tdap (61,394, 89%) or Td (7,521, 11%). There was no statistically significant increase in medical visits for cellulitis, limb swelling, pain in limb, seizure, cranial nerve disorders, paralytic syndromes, encephalopathy, encephalitis, or meningitis among those who received a subsequent dose of Tdap compared with those who received Td (29).…”

Section: Summary Of Key Findingsmentioning

confidence: 82%

“…Because of limited data on the use of >1 Tdap dose in the catch-up immunization schedule, the work group also considered published and unpublished safety data on receipt of >1 Tdap dose within a 12-month period in both pregnant women and nonpregnant adolescents and adults. Data from public sector orders (CDC, unpublished data, 2019), commercial insurance claims (Truven Health Analytics, unpublished data, 2019), and a published study from the Vaccine Safety Datalink (VSD) (29) were analyzed to assess stakeholders' values attributed to perceived benefits and harms, acceptability, and implementation considerations regarding use of Tdap in place of Td.…”

Section: Methodsmentioning

confidence: 99%

“…There was no significant difference in adverse events for subjects receiving 3 Tdap doses, compared with those receiving 3 Td doses, and no significant differences in diphtheria and tetanus seroprotection rates among the three groups (33). An analysis of data collected as part of a published VSD retrospective study (29) identified 13,599 persons who had received an initial dose of Tdap and then received another Td-containing vaccine within 12 months of the previous Tdap dose, either a second Tdap (11,687, 86%) or Td (1,912, 16%). There was no elevated risk for medical visits for adverse events among those who received a subsequent dose of Tdap compared with those who received Td (CDC/VSD, unpublished data, 2019).…”

Section: Summary Of Key Findingsmentioning

confidence: 98%

“…A VSD study examining safety of Tdap during pregnancy identified 187 women who had received >1 Tdap dose during a single pregnancy among 633,542 singleton pregnancies screened for potential study inclusion (36). Although these 187 women were excluded from the published study, the authors found similar rates of adverse birth outcomes (i.e., small for gestational age, preterm delivery, and low birthweight) in these women compared with women who had received a single Tdap dose in pregnancy (29,155). Among these 187 women who received >1 Tdap dose during pregnancy, one had a medically attended acute adverse event, which was diagnosed as limb pain and swelling 7 days after vaccination.…”

Section: Summary Of Key Findingsmentioning

confidence: 99%

“…In January 2019, FDA approved Adacel for a second Tdap dose if administered ≥8 years after the first Tdap dose and for use for tetanus prophylaxis when indicated for wound management if ≥5 years have elapsed since the previous receipt of any tetanus toxoid-containing vaccine (28). In light of the new indication for a second dose of Adacel and evidence of Tdap being used frequently in place of Td (29), ACIP reassessed current Tdap recommendations. In October 2019, ACIP recommended that either Tdap or Td vaccines could be used in situations where only Td vaccine had been recommended previously.…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Use of Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccines: Updated Recommendations of the Advisory Committee on Immunization Practices — United States, 2019

Havers¹,

Moro²,

Hunter³

et al. 2020

MMWR Morb. Mortal. Wkly. Rep.

128

View full text Add to dashboard Cite

Section: Summary Of Key Findingsmentioning

confidence: 82%

Section: Methodsmentioning

confidence: 99%

Section: Summary Of Key Findingsmentioning

confidence: 98%

Section: Summary Of Key Findingsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Use of Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccines: Updated Recommendations of the Advisory Committee on Immunization Practices — United States, 2019

Havers¹,

Moro²,

Hunter³

et al. 2020

MMWR Morb. Mortal. Wkly. Rep.

128

View full text Add to dashboard Cite

Improving vaccination rates in older adults and at-risk groups: focus on pertussis

Choi¹,

Sousa

Fletcher

et al. 2022

Aging Clin Exp Res

View full text Add to dashboard Cite

Despite the implementation of effective paediatric vaccination programmes, pertussis remains a global health problem. Disease epidemiology has changed over time, shifting towards the adolescent and adult populations. In adults, the true burden of pertussis is greatly underestimated and pertussis vaccine coverage rates are suboptimal, including individuals with chronic conditions. Here, we report the outcomes of a virtual international scientific workshop to assess the evidence on the burden of pertussis in older adults and identify potential solutions to improve uptake of pertussis vaccines. In adults, pertussis is underdiagnosed in part due to atypical or milder clinical presentation and the lack of testing and case confirmation. However, contemporary epidemiological data denoted an increase in the burden of pertussis among adolescents and adults. This might be related to a variety of reasons including the waning of immunity over time, the lack of booster vaccination, and the improved diagnostic methods that led to increased recognition of the disease in adults. Pertussis sequelae can be severe in older adults, particularly those with existing chronic medical conditions, and the vulnerability of these groups is further enhanced by low pertussis vaccine coverage. Possible measures to increase vaccine uptake include strengthening and harmonisation of immunisation guidelines, healthcare professionals taking a more active role in recommending pertussis vaccination, involvement of vaccination centres and pharmacies in the vaccination process, and improving knowledge of pertussis burden and vaccine efficacy among the general population.

show abstract

Adjuvants and delivery systems based on polymeric nanoparticles for mucosal vaccines

Jin

Gao

Cui

et al. 2019

International Journal of Pharmaceutics

View full text Add to dashboard Cite

Safety of repeated doses of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine in adults and adolescents

Cited by 7 publications

References 15 publications

Use of Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccines: Updated Recommendations of the Advisory Committee on Immunization Practices — United States, 2019

Use of Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccines: Updated Recommendations of the Advisory Committee on Immunization Practices — United States, 2019

Improving vaccination rates in older adults and at-risk groups: focus on pertussis

Adjuvants and delivery systems based on polymeric nanoparticles for mucosal vaccines

Contact Info

Product

Resources

About